[go: up one dir, main page]

PE20231503A1 - INHIBIDORES DE IL-11 O IL-11Ra PARA USO EN EL TRATAMIENTO DE SANGRADO UTERINO ANORMAL - Google Patents

INHIBIDORES DE IL-11 O IL-11Ra PARA USO EN EL TRATAMIENTO DE SANGRADO UTERINO ANORMAL

Info

Publication number
PE20231503A1
PE20231503A1 PE2023002423A PE2023002423A PE20231503A1 PE 20231503 A1 PE20231503 A1 PE 20231503A1 PE 2023002423 A PE2023002423 A PE 2023002423A PE 2023002423 A PE2023002423 A PE 2023002423A PE 20231503 A1 PE20231503 A1 PE 20231503A1
Authority
PE
Peru
Prior art keywords
bleeding
inhibitors
abnormal uterine
treatment
uterine bleeding
Prior art date
Application number
PE2023002423A
Other languages
English (en)
Inventor
Maik Stefan Wilheim Obendorf
Frank Sacher
Jorg Muller
Ralf Lesche
Christian Votsmeier
Stephan Marsch
Jan Tebbe
Philipp Ellinger
Patrick Michael Smith
Jenny Fitting
Katharina Filarsky
Mathias Gehrmann
Marcus Karlstetter
Ernst Weber
Mark Trautwein
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of PE20231503A1 publication Critical patent/PE20231503A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5431—IL-11
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/361—Menstrual abnormalities or abnormal uterine bleeding, e.g. dysmenorrhea

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta referido a un anticuerpo aislado o fragmento de union a antigeno del mismo capaz de unirse a IL-11 e inhibir la senalizacion mediada por IL-11, en donde dicho anticuerpo aislado o fragmento de union a antigeno del mismo es capaz de reducir la perdida de sangre durante el sangrado uterino anormal. Estos anticuerpos son inhibidores y antagonistas de la interleuquina-11 (IL-11) y/o del receptor alfa de la interleuquina-11 (IL-11RA) que incluyen inhibidores y antagonistas alostericos para el tratamiento y/o prevencion del sangrado uterino anormal, el cual comprende sangrado menstrual abundante, sangrado prolongado, patron de sangrado alterado, dismenorrea, asi como de las enfermedades subyacentes leiomioma y endometriosis y el uso del agente para inhibir la menstruacion.
PE2023002423A 2021-02-26 2022-02-24 INHIBIDORES DE IL-11 O IL-11Ra PARA USO EN EL TRATAMIENTO DE SANGRADO UTERINO ANORMAL PE20231503A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21159569 2021-02-26
PCT/EP2022/054612 WO2022180145A2 (en) 2021-02-26 2022-02-24 Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding

Publications (1)

Publication Number Publication Date
PE20231503A1 true PE20231503A1 (es) 2023-09-26

Family

ID=74797799

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023002423A PE20231503A1 (es) 2021-02-26 2022-02-24 INHIBIDORES DE IL-11 O IL-11Ra PARA USO EN EL TRATAMIENTO DE SANGRADO UTERINO ANORMAL

Country Status (13)

Country Link
US (2) US20240124572A1 (es)
EP (2) EP4298123A2 (es)
JP (1) JP2024512279A (es)
KR (1) KR20230150287A (es)
CN (1) CN117157317A (es)
AR (1) AR124989A1 (es)
AU (1) AU2022225064A1 (es)
CA (1) CA3211686A1 (es)
IL (1) IL305131A (es)
MX (1) MX2023009946A (es)
PE (1) PE20231503A1 (es)
TW (1) TW202302634A (es)
WO (2) WO2022180172A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022339767A1 (en) 2021-08-30 2024-04-11 Lassen Therapeutics 1, Inc. Anti-il-11rα antibodies
CN119080928A (zh) * 2023-06-05 2024-12-06 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的纯化方法
CN119424631A (zh) * 2023-07-28 2025-02-14 迈威(上海)生物科技股份有限公司 抗白介素-11抗体在制备肿瘤治疗药物中的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US5582821A (en) 1994-07-22 1996-12-10 Genetics Institute, Inc. Methods for treating bleeding disorders
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1998058964A1 (en) 1997-06-24 1998-12-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
IL136544A0 (en) 1997-12-05 2001-06-14 Scripps Research Inst Humanization of murine antibody
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2466106A1 (en) * 2001-11-06 2003-05-15 Applied Research Systems Ars Holding N.V. Methods of treating endometreosis
DE60301953T2 (de) 2002-03-05 2006-07-27 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
SI2289936T1 (sl) 2002-12-16 2017-10-30 Genentech, Inc. Imunoglobulinske variante in njihove uporabe
LT2077282T (lt) 2003-11-05 2017-03-10 Roche Glycart Ag Antigeną surišančios molekulės su padidintu fc receptoriaus surišimo giminingumu ir efektoriaus funkcija
WO2005098041A2 (en) 2004-03-26 2005-10-20 University Of Florida Research Foundation, Inc. Detection and treatment of fibrotic disorders
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008112640A2 (en) 2007-03-09 2008-09-18 Sinomab Bioscience Limited Construction and use of a functionally human antibody library with maximized repertoire diversity
CN104203981A (zh) 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
JP6545105B2 (ja) 2013-02-07 2019-07-17 シーエスエル、リミテッド Ｉｌ−１１ｒ結合タンパク質及びその使用
KR101565886B1 (ko) * 2013-10-23 2015-11-05 전남대학교산학협력단 난소과자극증후군의 진단 방법 및 키트
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
JP7181870B2 (ja) 2016-12-16 2022-12-01 シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド Ｉｌ－１１抗体
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
EP3600378A4 (en) * 2017-03-24 2020-12-23 Orpheus Bioscience Inc. PANTIDS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS
GB201716733D0 (en) * 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies

Also Published As

Publication number Publication date
JP2024512279A (ja) 2024-03-19
CN117157317A (zh) 2023-12-01
EP4298123A2 (en) 2024-01-03
AU2022225064A1 (en) 2023-08-10
WO2022180172A1 (en) 2022-09-01
WO2022180145A2 (en) 2022-09-01
CA3211686A1 (en) 2022-09-01
US20240124572A1 (en) 2024-04-18
AR124989A1 (es) 2023-05-24
MX2023009946A (es) 2023-09-04
TW202302634A (zh) 2023-01-16
IL305131A (en) 2023-10-01
KR20230150287A (ko) 2023-10-30
US20240317847A1 (en) 2024-09-26
WO2022180145A3 (en) 2022-10-27
EP4298124A1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
PE20231503A1 (es) INHIBIDORES DE IL-11 O IL-11Ra PARA USO EN EL TRATAMIENTO DE SANGRADO UTERINO ANORMAL
AR119389A1 (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
ECSP18047708A (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo como antagonistas de progesterona y procedimientos para su preparación
CL2021003327A1 (es) Anticuerpos anti - sortilina y métodos para su uso. (divisional de solicitud 202100089).
UY30525A1 (es) Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos
PE20180131A1 (es) Terapia de combinacion del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte programada 1 (pd 1) para el tratamiento del cancer
PE20160192A1 (es) Composiciones y metodo para tratar condiciones asociadas con el complemento
CL2020002047A1 (es) Métodos terapéuticos y diagnósticos para enfermedades inflamatorias mediadas por mastocitos.
EA202190591A1 (ru) Удаление менструальной жидкости
BR112018012626A2 (pt) ccl20 como um preditor de resposta clínica a antagonistas de il23
SV2006002342A (es) Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
ECSP22015044A (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
MX2020004421A (es) Biomarcadores de parto prematuro.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
DK1879572T3 (da) Anvendelse af antagonister af oxytocin og/eller vasopressin i kunstig befrugtning
PE20191746A1 (es) Inhibidores y antagonistas de gpr84 para el tratamiento de endometriosis
MX2020013894A (es) Anticuerpos anti-factor xii/xiia y usos de los mismos.
MX2021003127A (es) Uso de un inhibidor de catepsina s contra la formacion de anticuerpos antifarmaco.
MX2018006250A (es) Biomarcador de enfermedad poliquistica renal y usos del mismo.
CL2022002830A1 (es) Anticuerpo anti-ox40 y usos del mismo
BR112019024230A2 (pt) combinação de um anticorpo bispecífico erbb-2 / erbb-3 com terapia endócrina para câncer de mama
MX2024004447A (es) Anticuerpos dirigidos a ccr2.
BR112019001047A2 (pt) método para tratar um indivíduo submetido à terapia de transferência de embriões e kit
AR095834A1 (es) Forma de dosificación de un antagonista del receptor de progesterona, composición farmacéutica
PE20230765A1 (es) Anticuerpo anti-cd47 y usos del mismo